Robert W. Baird Trims Twist Bioscience (NASDAQ:TWST) Target Price to $33.00

Twist Bioscience (NASDAQ:TWSTGet Rating) had its target price decreased by Robert W. Baird from $56.00 to $33.00 in a report released on Monday, The Fly reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research analysts also recently commented on the company. Barclays reduced their target price on Twist Bioscience from $45.00 to $43.00 and set an overweight rating on the stock in a report on Monday. SVB Leerink reduced their target price on Twist Bioscience from $45.00 to $30.00 and set a market perform rating on the stock in a report on Monday.

Twist Bioscience Stock Up 1.3 %

Shares of NASDAQ TWST opened at $25.53 on Monday. Twist Bioscience has a fifty-two week low of $23.90 and a fifty-two week high of $99.74. The business has a 50 day moving average price of $32.37 and a two-hundred day moving average price of $36.79. The firm has a market cap of $1.44 billion, a PE ratio of -6.33 and a beta of 1.15.

Insider Buying and Selling

In related news, SVP Paula Green sold 8,514 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $37.43, for a total value of $318,679.02. Following the sale, the senior vice president now owns 14,199 shares of the company’s stock, valued at approximately $531,468.57. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 9,211 shares of company stock valued at $341,371. Insiders own 3.10% of the company’s stock.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. Captrust Financial Advisors increased its position in Twist Bioscience by 101.3% in the 2nd quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after acquiring an additional 382 shares during the period. Advanced Research Investment Solutions LLC acquired a new stake in Twist Bioscience in the 1st quarter valued at approximately $35,000. National Bank of Canada FI increased its position in Twist Bioscience by 3,333.3% in the 2nd quarter. National Bank of Canada FI now owns 1,030 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares during the period. CWM LLC increased its position in Twist Bioscience by 430.7% in the 2nd quarter. CWM LLC now owns 1,226 shares of the company’s stock valued at $43,000 after acquiring an additional 995 shares during the period. Finally, Canada Pension Plan Investment Board increased its position in shares of Twist Bioscience by 155.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 1,066 shares of the company’s stock valued at $52,000 after purchasing an additional 649 shares during the period.

About Twist Bioscience

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Articles

The Fly logo

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.